Among identified genes, TERT expression and TERC overexpression showed independent predictive impacts on progression free survival, which, together with the age at diagnosis, held a moderate discriminatory power for distinguishing tumours from patients with excellent response after initial treatment (median follow‐up >8 years) from those with increased morbidity and associated high health care cost (evidence of disease, recurrence or/and disease specific mortality during the follow‐up). This evidence concerns the gene TERC and neoplasm.